Abstract

Tocilizumab, an interleukin-6 inhibitor, may enhance clinical outcomes by reducing the inflammatory symptoms of severe coronavirus disease 2019 (COVID-19). The reported patients with laboratory-confirmed severe COVID-19 who received tocilizumab and followed up for 14 days were studied retrospectively. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilator support requirements. In this work our aim is to conclude that at what stage tocilizumab is used and what outcomes are observed.